Amryt Pharma

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Founded in 2011, Amryt has launched two treatments for rare and orphan diseases: Lojuxta and metreleptin. The company has acquired three other pharmaceutical companies, passing a wide range of products and pipeline candidates.

To develop and deliver life-changing treatments that are tailored to meet the needs of people living with rare and life-threatening diseases.

To be a leading global rare and orphan drug company.

Amryt is the recipient of the 2018 EY Emerging Entrepreneur Award and the 2017 Plattner EuropeanHealth Award.